A Meta-analysis of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting

Overview

Journal Sci Rep

Specialty Science

Date 2014 Apr 29

PMID 24770591

Citations 15

Authors

Xiao-Fei Wang

Yun Feng

Ying Chen

Bei Li Gao

Bao-Hui Han

Affiliations

Soon will be listed here.

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life and is one of the reasons for the discontinuation of treatment. Olanzapine is known as an atypical antipsychotic agent, but it has been reported to be effective in treating refractory CINV due to its broad and potent inhibitory activity at multiple receptors involved in the nausea and vomiting pathways. This study was conducted to assess the efficacy of olanzapine for the prevention of CINV after moderately or highly emetogenic chemotherapy. After a search of Medline (Ovid), PubMed, CNKI, Wanfang and Weipu from 1990 to October 2013, all randomised controlled trials of olanzapine for the prevention of CINV were included in this study. The meta-analysis was performed using RevMan 5.0.19 software. 6 studies involving 726 total patients were included, of which 441 were Chinese oncology patients. We found that for both general populations and Chinese populations, antiemetic regimens including olanzapine are more effective at reducing CINV than regimens that do not include olanzapine, especially in the delayed phase of CINV.

Citing Articles

Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug.

Zhang X, Ying J Curr Oncol. 2022; 29(11):8235-8243.

PMID: 36354710 PMC: 9689588. DOI: 10.3390/curroncol29110650.

[Prophylaxis of nausea and vomiting after medical cancer treatment : Guidelines on supportive treatment-Part II].

Link H Urologie. 2022; 61(6):667-680.

PMID: 35925083 DOI: 10.1007/s00120-022-01848-x.

Olanzapine enhances the effect of conventional drugs in chemotherapy inducing nausea and vomiting: A randomized clinical trial.

Khani A, Eishy Oskuyi A, Asghari R, Khalkhli H, Sharifi H Caspian J Intern Med. 2022; 13(2):356-362.

PMID: 35919648 PMC: 9301225. DOI: 10.22088/cjim.13.2.6.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.

Osman A, Elhassan M, AbdElrahim B, Ahmed F, Yousif J, Ahmed M J Glob Oncol. 2018; 4:1-9.

PMID: 30241275 PMC: 6223527. DOI: 10.1200/JGO.17.00216.

Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.

Chanthawong S, Lim Y, Subongkot S, Chan A, Andalusia R, Ahmad Bustamam R Support Care Cancer. 2018; 27(3):1109-1119.

PMID: 30112718 DOI: 10.1007/s00520-018-4400-1.

References

Navari R, Gray S, Kerr A . Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011; 9(5):188-95. DOI: 10.1016/j.suponc.2011.05.002. View

Hesketh P . Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358(23):2482-94. DOI: 10.1056/NEJMra0706547. View

Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H . Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009; 28:131. PMC: 2761865. DOI: 10.1186/1756-9966-28-131. View

Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N . Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2013; 47(3):542-50. DOI: 10.1016/j.jpainsymman.2013.05.003. View

Licup N . Olanzapine for nausea and vomiting. Am J Hosp Palliat Care. 2010; 27(6):432-4. DOI: 10.1177/1049909110369532. View

Navari R . Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw. 2007; 5(1):51-9. DOI: 10.6004/jnccn.2007.0007. View

Ettinger D, Armstrong D, Barbour S, Berger M, Bierman P, Bradbury B . Antiemesis. J Natl Compr Canc Netw. 2012; 10(4):456-85. DOI: 10.6004/jnccn.2012.0047. View

Passik S, Navari R, Jung S, Nagy C, Vinson J, Kirsh K . A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004; 22(3):383-8. DOI: 10.1081/cnv-200029066. View

Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzales G . Olanzapine in the management of cancer pain. J Pain Symptom Manage. 2002; 23(4):346-50. DOI: 10.1016/s0885-3924(02)00378-0. View

10.

Bymaster F, Calligaro D, Falcone J, Marsh R, Moore N, Tye N . Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996; 14(2):87-96. DOI: 10.1016/0893-133X(94)00129-N. View

11.

Pirl W, Roth A . Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology. 2000; 9(1):84-7. DOI: 10.1002/(sici)1099-1611(200001/02)9:1<84::aid-pon440>3.0.co;2-t. View

12.

Bloechl-Daum B, Deuson R, Mavros P, Hansen M, Herrstedt J . Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006; 24(27):4472-8. DOI: 10.1200/JCO.2006.05.6382. View

13.

Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J . Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer. 1997; 5(4):307-13. DOI: 10.1007/s005200050078. View

14.

Allison D, Casey D . Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001; 62 Suppl 7:22-31. View

15.

Herrstedt J, Dombernowsky P . Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007; 101(3):143-50. DOI: 10.1111/j.1742-7843.2007.00122.x. View

16.

Fulton B, Goa K . Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997; 53(2):281-98. DOI: 10.2165/00003495-199753020-00007. View

17.

Passik S, Lundberg J, Kirsh K, Theobald D, Donaghy K, Holtsclaw E . A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002; 23(6):526-32. DOI: 10.1016/s0885-3924(02)00391-3. View

18.

Jackson W, Tavernier L . Olanzapine for intractable nausea in palliative care patients. J Palliat Med. 2003; 6(2):251-5. DOI: 10.1089/109662103764978506. View